Showing results (1-10 of 210) with videos related to
Sort By:
Pageof 21
Clinical and Experimental Immunology|June 1, 1996
Characterization of a soluble form of CD58 in synovial fluid of patients with rheumatoid arthritis (RA)J C Hoffmann, B Bayer, H ZeidlerJournal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|December 17, 2008
Poststreptococcal erythema nodosum and arthritis in two elderly womenJ C Hoffmann, W Mau, H ZeidlerClinical and Experimental Immunology|November 14, 1997
Anti-CD2 (OX34) MoAb treatment of adjuvant arthritic rats: attenuation of established arthritis, selective depletion of CD4+ T cells, and CD2 down-modulationJ C Hoffmann, C Herklotz, H Zeidler, et al.Cell Biology International|November 26, 1998
Human b cell differentiation: dependence on interactions with monocytes and T lymphocytes via CD40, CD80 (B7.1), and the CD2-Ligands CD48 and CD58 (LFA-3)J C Hoffmann, H Krüger, S Zielen, et al.Clinical and Experimental Rheumatology|January 1, 1996
Decreased levels of a soluble form of the human adhesion receptor CD58 (LFA-3) in sera and synovial fluids of patients with rheumatoid arthritisJ C Hoffmann, H J Räuker, H Krüger, et al.Annals of the New York Academy of Sciences|February 3, 1999
Effects of the anti-CD2 mAb OX34 on in vivo proliferationJ C Hoffmann, C Herklotz, M Zeitz, et al.Annals of the Rheumatic Diseases|March 13, 1998
Initiation and perpetuation of rat adjuvant arthritis is inhibited by the anti-CD2 monoclonal antibody (mAb) OX34J C Hoffmann, C Herklotz, H Zeidler, et al.Arthritis and Rheumatism|August 1, 1995
Lyme disease in a 74-year-old forest owner with symptoms of dermatomyositisJ C Hoffmann, D O Stichtenoth, H Zeidler, et al.Das Offentliche Gesundheitswesen|October 1, 1989
[Social medicine results of expert assessment of work disability]H ZeidlerWiener Klinische Wochenschrift. Supplementum|January 1, 1984
[Experiences to date with oral gold therapy]H ZeidlerPageof 21